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Conatus 14: Multicenter randomized controlled study comparing emricasan, (a caspase inhibitor) at 3 
different doses vs. placebo in patients with NASH cirrhosis and severe portal hypertension
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Background and Aim: Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in 
experimental cirrhosis and in patients with cirrhosis and portal pressure (assessed by the hepatic 
venous pressure gradient [HVPG]) ≥12 mmHg.  We aimed to confirm these results in a 
randomized, placebo-controlled, double blind study. 
Methods: Multicenter study including 263 patients with cirrhosis due to non-alcoholic 
steatohepatitis (NASH) and baseline HVPG ≥12 mmHg randomized 1:1:1:1 to emricasan 5 
(n=65), 25 (n=65), 50 (n=66) mg or placebo (n=67) orally twice daily for up to 48 weeks. 
Primary endpoint was change in HVPG (∆HVPG) at week 24. Secondary endpoints were 
changes in biomarkers (aminotransferases, caspases, cytokeratins) and development of liver-
related outcomes. 
Results: There were no significant differences in ∆HVPG for any emricasan dose vs. placebo (-
0.21, -0.45, -0.58 mmHg, respectively) adjusted by baseline HVPG, compensation status, and 
non-selective beta-blocker use. Compensated subjects (n=201 [76%]) tended to have a greater 
decrease in HVPG (emricasan all vs. placebo, p=0.06), the decrease being greater in those with 
higher baseline HVPG (p=0.018), with a significant interaction between baseline HVPG 
(continuous, p=0.024; dichotomous at 16 mmHg [median], p=0.013) and treatment. Biomarkers 
decreased significantly with emricasan at week 24 but returned to baseline levels by week 48. 
New or worsening decompensating events (~10% over median exposure of 337 days), 
progression in MELD and Child Pugh scores, and treatm nt-emergent adverse events were 
similar among treatment groups. 
Conclusions: Despite reduction in biomarkers indicating target engagement, emricasan was not 
associated with improvement in HVPG or clinical outcomes in patients with NASH cirrhosis and 
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severe portal hypertension. Compensated subjects with higher baseline HVPG had evidence of a 





Cirrhosis (scarring of the liver) is the main consequ nce of non-alcoholic steatohepatitis (NASH)  
Cirrhosis leads to high pressure in the portal vein and this accounts for most of the complications 
of cirrhosis.  Reducing portal pressure is beneficial in patients with cirrhosis. We studied the 
possibility that emricasan, a drug that improves inflammation and scarring in the liver, would 
reduce portal pressure in patients with NASH cirrhosis and severe portal hypertension.  Our 
results in a large, prospective, double-blind study could not demonstrate a beneficial effect of 







Cirrhosis due to non-alcoholic fatty liver disease is fast becoming a major disease burden 
worldwide (1). In fact, non-alcoholic steatohepatitis (NASH) is a leading indication for liver 
transplantation in the U.S. (2). Portal hypertensio is a key driver of the major complications of 
cirrhosis that define decompensation, the latter being the main predictor of death in cirrhosis. (3, 
4) A portal pressure (determined by the hepatic venous pressure gradient [HVPG]) ≥10 or ≥12 
mmHg is the strongest predictor of decompensation in patients with mostly viral-induced 
cirrhosis (4), but also in patients with NASH cirrhosis (5). Importantly, decreases in HVPG are 
associated with lower rates of decompensation and death in compensated and decompensated 
patients (6). There are currently no approved therapi s that can ameliorate the abnormalities 
leading to significant portal hypertension in NASH cirrhosis patients.  
Emricasan is an oral pan-caspase inhibitor that decreased excessive apoptosis, 
inflammation, and fibrosis in animal models of NASH and decreased portal pressure and/or 
improved survival in rodent models of cirrhosis (7, 8). A 28-day open-label study of emricasan 
(25 mg orally twice daily) in 22 patients with compensated cirrhosis (primarily due to NASH or 
HCV) demonstrated clinically meaningful decrease in mean HVPG of -3.7 mmHg in a subgroup 
with baseline HVPG ≥12 mmHg, with concomitant decreases in aminotransfera es that 
suggested an intrahepatic anti-inflammatory effect (9). 
We now report the results of a randomized, double-blind, placebo-controlled multicenter 
trial of emricasan in NASH cirrhosis patients with severe portal hypertension (HVPG ≥12 
mmHg). This study focused on patients with compensated cirrhosis but also enrolled ~25% 
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decompensated patients (with no more than one decompensating event) to determine if similar 
efficacy would be observed.  
 
Patients and Methods 
Study Oversight 
 The study was designed by expert clinicians who had experience in cirrhosis and portal 
hypertension in collaboration with representatives from the Sponsor. The study protocol was 
approved by the institutional review boards and ethics committees at each participating site prior 
to study initiation. The study was conducted in accordance with standards that met applicable 
regulations, including the International Conference on Harmonization Guideline for Good 
Clinical Practice. All patients provided written informed consent prior to participation in the 
study. Data were collected by investigators. An independent Data Monitoring Committee 
regularly reviewed unblinded safety data from the study. A separate independent Hepatic 
Adjudication Committee reviewed in a blinded fashion cases that met protocol-specified criteria 
for closer monitoring of elevated liver tests. Authors from the Sponsor had access to all data and 
vouch for the integrity of the data analyses. All authors participated in the drafting and/or review 
of the manuscript and provided final approval to submit. No medical writer was involved in the 
manuscript development.  
Study Design 
Across 59 sites in the US, Spain, France, Germany, and Switzerland, NASH cirrhosis patients 
with screening HVPG ≥12mmHg were randomized 1:1:1:1 to emricasan 5 mg, 25 mg, or 50 mg 
or matching placebo orally twice daily for 24 weeks with HVPG performed again at week 24. 
Patients were stratified by baseline compensated vs. ecompensated status and by use of non-
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selective beta-blockers (NSBB) or not. The Sponsor u ed a validated Interactive Web Response 
System with strict quality control procedures for central coordination and random assignment of 
subjects to emricasan or placebo. Study participants, site personnel, and the Sponsor were all 
blinded to treatment group assignment. After completing week 24, subjects were eligible to 
continue the same randomized blinded treatment for an additional 24 weeks. Emricasan doses 
selected were based on dose-response modelling usin biomarkers (ALT, AST, cCK18, caspase 
3/7) in earlier Phase 1 and 2 studies (primarily patients with chronic liver disease due to HCV 
infection) and based on the dose (25 mg) used in the prior open-label study (9).  
The primary endpoint of the study was to compare the change in HVPG from baseline to 
week 24 between emricasan and placebo.  Secondary endpoints were a) to assess the safety and 
tolerability of emricasan, b) to characterize the dose-response of emricasan on portal pressure as 
assessed by HVPG at Week 24, c) to assess whether emricasan compared to placebo improves 
HVPG response at Week 24 using a 20% reduction frombaseline response definition, and d) to 
assess whether emricasan compared to placebo decreas s mechanism specific (caspase 3/7) and 
non-specific alanine aminotransferase (ALT) biomarkers at Weeks 24 and 48.  Exploratory 
endpoints were to assess whether emricasan compared to placebo decreases development of 
decompensation or worsening of decompensation and to assess whether emricasan compared to 
placebo improves liver function and prognosis at Weeks 24 and 48 as assessed by model for end-
stage liver disease (MELD) and Child-Pugh (C-P) scores.  
 
Patient Population 
Key inclusion criteria were: cirrhosis due to NASH with exclusion of other causes of 
cirrhosis, compensated or decompensated (no more than one decompensating event), HVPG ≥12 
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mmHg, on stable medications (NSBB, nitrates, diuretcs, lactulose, rifaximin, statins) at least 3 
months. At least 60% subjects but no more than 75% were to have compensated cirrhosis. The 
presence or absence of varices was not a selection criterion. A complete list of inclusion and 
exclusion criteria, including criteria for decompensating events, is provided (Table S1). All 
versions of the protocol are published online as supplementary information (Supplementary 
CTAT table). 
Study Procedures 
After a 6-week screening period, eligible subjects were randomized and seen at study 
visits in an outpatient setting every 4 weeks during the initial 24-week phase and every 8 weeks 
during the second 24-week phase, with a follow-up visit off study drug ~2 weeks after the last 
visit. At each study visit, vital signs, MELD, and Child-Pugh status were assessed, and blood 
samples obtained for routine chemistries, hematology, coagulation, and biomarkers (including 
caspase 3/7, cCK18, flCK18). Transient elastography to assess liver stiffness was performed at 
screening, week 24, and week 48 at a subset of sites. Subjects were assessed for the occurrence 
of clinical outcome events (new or worsening decompensation) throughout the study. Worsening 
decompensation was defined as worsening ascites requiring paracentesis (in subjects with prior 
history of ascites), recurrent variceal hemorrhage (VH) (in subjects with prior history of VH) or 
worsening hepatic encephalopathy (HE) requiring hospitalization (in subjects with prior history 
of HE).  
HVPG was done at the end of screening (baseline) and again at week 24. All HVPG 
measurements were performed and pressure tracings recorded according to standard operating 
procedure outlined in a study manual provided to sites and following didactic training. Each 
study site provided an acceptable sample HVPG tracing prior to patient enrollment. Portal 
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pressure was determined indirectly by the HVPG, as previously described (10). Using the 
transjugular approach, a balloon-tipped catheter was advanced into a hepatic vein under 
fluoroscopic guidance. The free hepatic venous pressur  (FHVP) was measured with the balloon 
deflated, and the wedged hepatic venous pressure (WHVP) with the balloon inflated until the 
branch of hepatic vein was completely occluded. HVPG was obtained by subtracting FHVP from 
WHVP. Measurements were performed in triplicate. Tracings were read independently by a 
single experienced investigator (GGT) who provided a subjective assessment of the overall 
quality (excellent, very good to good, or fair) and if significant variability was present. Only 
subjects with screening HVPG assessed at least fair in quality were eligible for randomization. 
Clinical laboratory tests and biomarker measurements were performed by PPD Labs 
(Highland Heights, KY, USA; Zaventem, Belgium). Keratin-18 is a major cytoplasmic 
intermediate filament protein cleaved by executioner caspases during apoptosis and cell death. 
Fulllength keratin-18 (flCK18) and caspase cleaved keratin-18 (cCK18) were quantified using 
ELISA detecting the M65 (VLVbio, reference range: 115413 U/L) and M30 (VLVbio, 
reference range: <260 U/L) epitopes, respectively. Caspase-3/7 activity (Promega, reference 
range: 14293908 relative light units) detects activity of the executioner caspases-3 and -7. 
Statistical Analyses 
The primary analysis was performed after the collection of all week 24 HVPG data. A 
final analysis was performed after the study was completed. Data (mean [SD] or N [%]) are 
summarized by treatment group (emricasan 5 mg, 25 mg, 50 mg, placebo) as well as for all 3 
emricasan doses together (referred to as “emricasan ll”).  
The primary endpoint (mean change in HVPG from baseline to week 24) was analyzed 
using a fixed effects analysis of covariance (ANCOVA) model in the full analysis set, which 
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included all randomized subjects receiving at least 1 dose of study drug, comparing the change 
from baseline in HVPG for each emricasan dose vs. placebo, adjusting for baseline HVPG, 
baseline compensated vs. decompensated status, and baseline NSBB use. A one-step Dunnett’s 
test adjusted for multiple comparisons of emricasan doses vs. placebo. Using multiple 
imputation, missing data for HVPG was imputed a priori based on demographic and baseline 
clinical factors (i.e. age, gender, compensated status, MELD, Child-Pugh). A per-protocol 
analysis (for the primary endpoint only) was also performed excluding subjects with missing 
week 24 HVPG, significant non-compliance with study drug, or significant confounders such as 
initiation of NSBB after the screening HVPG. Pre-specified sub-group analyses were performed 
in compensated, decompensated, and treated or not with NSBB. Ad-hoc analyses were 
performed in compensated subjects according to baseline HVPG and presence or absence of 
varices. All subgroup analyses were performed with ANCOVA using observed data and 
adjusting only for baseline HVPG, with nominal p-values reported for informational purposes 
only. HVPG responder analyses were performed using a fixed effects logistic regression model 
using observed data and adjusting only for baseline HVPG. Three different published responder 
criteria were used: 1) decrease ≥20% or to <12 mmHg (6), 2) decrease ≥10% or to <12 mmHg 
(6), and 3) decrease ≥10% or to <10 mmHg (11).  Ad-hoc analyses of mean change in HVPG 
according to biomarker (caspase 3/7, cCK18, flCK18, ALT) response was performed, where the 
biomarker response was defined (arbitrarily) as ≥20% decrease from baseline at 1) all visits from 
weeks 4 to 24, or 2) at least 4 of 6 visits from week 4 to 24) were performed. 
Continuous secondary endpoints were analyzed using ANCOVA adjusting for baseline 
value with log-transformation (e.g. biomarkers) as appropriate. Binary secondary endpoints (e.g. 
clinical outcome events, MELD progression) were analyzed using a logistic regression model, 
12 
 
adjusting for baseline value. No multiplicity adjustment or imputation methods were used for 
analysis of secondary endpoints. Clinical outcome events included new or recurrent VH, new 
onset ascites requiring chronic diuretics, worsening ascites requiring paracentesis, new onset or 
worsening HE requiring hospitalization. For compensated subjects who experienced a new 
decompensation event that subsequently met criteria for worsening, both new and worsening 
events were included in the analysis. The occurrence of linical outcome events was analyzed 
based on subject incidence by the end of the study as well as based on an ad hoc time-to-event 
analysis. Pre-specified analyses of MELD and Child-Pugh evaluated the number of subjects 
having 4-point MELD or 2-point Child-Pugh progression. Ad-hoc analyses evaluated the number 
of compensated subjects with baseline MELD score ≤12 reaching MELD ≥15 and the number of 
baseline Child-Pugh A subjects progressing to Child-Pugh B. 
A sample size of 192 (48 per group) subjects was estimated to provide 80% power to 
detect a statistically significant difference between at least one emricasan dose vs. placebo in the 
mean change from baseline in HVPG, assuming a difference of 3 mmHg and standard deviation 
of 4.5 mmHg, at the conventional alpha=0.05.  Assuming an attrition rate of 20%, the sample 




A total of 564 subjects signed informed consent and were screened between October 
2016 and March 2018, with 263 randomized and treated with study drug, with the last subject 
follow-up visit occurring in April 2019 (Fig. S1). The most common reason for screen failure 
was not meeting HVPG ≥12 mmHg (N=137 [45.5%]). Of the 263 randomized, 250completed 
the initial 24-week phase, 236 consented to the second 24-week phase, and 219 completed week 
13 
 
48. Evaluable HVPG data was available for 243 subjects (N=13 not done due to subject not 
completing week 24, N=4 not done for other reasons, N=3 HVPG tracing not evaluable) (Fig. 
S1).  Of the 263 patients randomized, 124 (47.1%) subjects reported a biopsy showing NASH 
features (of these, 52 had biopsy only, whereas 72 had both biopsy and at least 2 metabolic 
features), 126 (47.9%) had >=2 metabolic features alone (without biopsy) and 13 (4.9%) had 
biopsy showing some but not all NASH features with fatty liver or at least 1 metabolic feature. 
Subject Demographics and Baseline Characteristics 
Demographics and baseline characteristics were generally balanced across treatment 
groups (Table 1). Overall, mean age was 61 years, with 57% female and 91% Caucasian. The 
majority (76%) had compensated cirrhosis and 24% had decompensation (28% prior VH, 40% 
diuretic-responsive ascites, 32% history of ≥grade 2 HE). Mean MELD score was 9, and 88% 
were CP A at baseline. Most subjects had varices (71% compensated, 76% decompensated) with 
41% treated with NSBB. Mean liver stiffness (assessed by transient elastography) was 38.8 kPa, 
and mean platelet count was 98 K/mm3. The majority (75%) had at least 2 metabolic risk factors 
for NASH for at least 5 years preceding cirrhosis, including diabetes (79%), hypertension (76%), 
and obesity (82%) with mean BMI of 35.3 kg/m2. Mean cCK18 and flCK18 were moderately 
elevated, and mean caspase 3/7 was mildly elevated. M an (SD) HVPG for all subjects was 17 
(3.6) mmHg (range 12.0 to 27.5 mmHg). 
Primary Efficacy Endpoint: HVPG 
In the overall patient population, there was no statistically significant change in HVPG at 
week 24 for any emricasan dose compared to placebo, with least squares mean (LSM) difference 
and 95% confidence intervals of -0.21 (-1.4, 0.95), -0.45 (-1.6, 0.72), -0.58 (-1.7, 0.59) mmHg 
for emricasan 5 mg, 25 mg, and 50 mg, respectively (Table 2, Fig. 1). The change in HVPG 
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ranged from approximately -5 mmHg to +5 mmHg in placebo subjects (Fig. 2A). Similar results 
were obtained in the per-protocol analysis. In addition, sensitivity analyses excluding HVPGs 
assessed as “fair” quality and excluding HVPGs with s gnificant variability showed similar 
results as the primary analysis (data not shown).  
Compensated subjects tended to have a greater decreas  in HVPG (LSM difference of -
0.94 mmHg vs. placebo, p=0.06) when all emricasan doses were combined (Table 2, Fig. 1). 
This trend to greater decrease in HVPG with emricasan was more prominent in those with 
varices (Table 2). In decompensated patients, there appeared to be a dose response with greater 
decrease from baseline in HVPG with emricasan 50 mg, but the placebo group had an 
unexpectedly large mean decrease in HVPG (2.6 mmHg) that rendered the LSM differences in 
HVPG between emricasan and placebo non-significant. There were no significant differences in 
HVPG between emricasan and placebo according to NSBB use. HVPG responder analyses 
showed similar findings for all subjects and compensated and decompensated subgroups with a 
non-significant trend for more responders with emricasan, especially in compensated subjects 
(Table S2).  
Given the trend for a greater decrease in HVPG withemricasan in compensated subjects, 
we evaluated if there were factors that predicted likelihood of better response (i.e. greater 
decrease in HVPG) and found that baseline HVPG was the trongest predictor. In compensated 
subjects, baseline HVPG (as a continuous variable) was a significant covariate for HVPG change 
at week 24 (p=0.0002) using a model that included all 4 treatment groups. In a model combining 
the 3 emricasan doses, baseline HVPG remained a significant covariate (p=0.018). In addition, 
there was a significant interaction between treatmen  and baseline HVPG, whether baseline 
HVPG was treated as a continuous variable (p=0.024) or dichotomized by the median value of 
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16 mmHg (p=0.013). Compensated subjects with baseline HVPG ≥16 mmHg had LSM 
difference in HVPG of -2.2 mmHg (95% CI: -3.5, -0.8) with emricasan all vs. placebo (Table 2, 
Fig. 1). In contrast, a model that assessed the interaction between treatment and baseline HVPG 
in compensated subjects did not find a significant interaction between treatment and presence of 
varices (p=0.21).  
Since baseline HVPG was a significant covariate, we evaluated the correlation between 
change in HVPG at week 24 vs. baseline HVPG (Fig. 2). In placebo subjects, change in HVPG 
at week 24 was not correlated with baseline HVPG (r=-0.12), but for all three emricasan doses, 
there was a greater decrease in HVPG at week 24 with higher baseline HVPG, particularly at 50 
mg (r=-0.42) (Fig. 2A). A similar pattern was observed in compensated subjects (Fig. 2B). 
However, the strongest correlation was only -0.43.   
  
Secondary and Exploratory Endpoints 
The rate of clinical outcome events (occurring at any time during the study) was not 
different between emricasan and placebo (Table 3). Similar results were obtained when analyzed 
according to a time-to-event analysis (data not shown). The overall subject incidence of events 
was low at ~10% (median exposure of 337 days), witha lower rate of new events in 
compensated (7%) compared to new or worsening events in decompensated subjects (21%). In 
the latter group, occurrence of a new type of decompensation was slightly higher numerically 
than worsening of an existing decompensation (13% vs. 8%). Further detail on the specific type 
of new or worsening event is provided in Table S3.  
In addition, the incidence of subjects with a ≥4-point MELD progression, ≥2-point Child-
Pugh progression, or progression from Child-Pugh A to B was similar between emricasan all vs. 
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placebo (Table 3). MELD progression to ≥15 (in compensated with baseline ≤12), which has 
been proposed as a transplant listing surrogate, was similar to the incidence of new or worse 
decompensation events (9.0% in emricasan all vs. 7.5% in placebo by week 48).  
Liver function tests (bilirubin, albumin, INR) and creatinine remained stable without 
significant difference among treatments (Table 4). There were no meaningful treatment 
differences in other clinical and laboratory parameters including heart rate, weight, liver 
stiffness, and platelet count (Table 4), except for a difference in mean systolic blood pressure of 
3 mmHg (-1.7 in emricasan all vs. -4.7 in placebo) due mainly to an increase (relative to placebo) 
in the emricasan 50 mg group.  
 Emricasan 25 and 50 mg treatment led to rapid and significant decreases in average 
caspase 3/7 values that were sustained to week 48, except for the 5 mg dose group that had an 
initial decrease at week 4 but not by week 24 (Fig. 3A-B, S2A). cCK18, flCK18, ALT, and AST 
also generally showed significant average decreases at week 24 with emricasan vs. placebo, but 
these changes were generally no longer different from placebo by week 48 (Fig. 3A-B, S2B-E).  
Biomarker (caspase 3/7, ALT, CCK18, flCK18) “responders” (defined arbitrarily as those who 
maintained levels ≥20% from baseline for all or most of visits through week 24) tended to have a 
greater decrease in HVPG compared to biomarker non-responders (Table S4). 
 
Safety 
Table 5 presents a summary of treatment-emergent adverse events (TEAEs). In the 
emricasan all and placebo groups, 91% of subjects rported at least one TEAE, with most 
(~80%) being mild or moderate in severity. The incidence of TEAEs leading to study 
discontinuation was slightly higher with emricasan all vs. placebo (without any dose response or 
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specific system clustering or pattern), but similar between emricasan all and placebo for TEAEs 
leading to discontinuation of study drug. The incidence of serious TEAEs was slightly higher in 
emricasan 25 mg (33.8%) and 50 mg (30.3%) vs. placebo (22.4%) whereas emricasan 5 mg was 
similar (21.5%) to placebo. Of serious TEAEs that occurred in more than 1 subject, VH was 
reported in 9 (4.6%) emricasan subjects (N=4 [5 mg], N=5 [25 mg]), pneumonia in 5 (2.6%) 
emricasan subjects (N=2 [5 mg], N=3 [50 mg]), and cellulitis in 4 (2.0%) emricasan (N=1 [5 
mg], N=2 [25 mg], N=1 [50 mg]). For all other serious TEAEs, there was no difference more 
than 3 between emricasan all vs. placebo. There wer4 deaths during the study (1 in emricasan 5 
mg, 2 in 25 mg, 1 in 50 mg), all assessed as unrelated to study drug. 
TEAEs were generally balanced between treatment groups across different system organ 
classes. No imbalance for serious TEAEs in other systems of interest, e.g. gastrointestinal and 
malignancies, was observed. More infection serious TEAEs were observed with emricasan but 
these were generally single cases (except pneumonia and cellulitis as noted) without any unusual 
types of infections. When considering all infection TEAEs (not only serious events), there was 
no imbalance between treatment groups. For frequent TEAEs (occurring in >5% of all subjects), 
peripheral edema, upper abdominal pain, and muscle spasms were more frequent with emricasan, 
while diarrhea, HE, anemia, and back pain were more frequent with placebo.  
Finally, there was no imbalance in liver test elevations that triggered additional monitoring 
(with or without interruption of study drug). Two subjects on emricasan (1 on 25 mg, 1 on 50 
mg) had increases in aminotransferases and total bilirubin meeting criteria for possible Hy’s law. 
Both cases were reviewed by an independent adjudication committee (blinded to study drug 
assignment) and assessed as more likely due to autoimmune hepatitis or progression of 
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underlying NASH, but a possible contribution of study drug could not be entirely excluded. 
There was no safety concern based on review of routine lab tests, vital signs, and ECG. 
 
Discussion 
The main strategy in treating cirrhosis is to contrl/eliminate the etiologic agent and 
ameliorate portal hypertension, the main driver of cirrhosis decompensation. In addition to 
treating etiological therapy, portal pressure-reducing therapies such as NSBB, decrease the risk 
of developing complications of cirrhosis (6, 11, 12) and are recommended in subjects with high-
risk varices (13). Portal pressure-reducing therapis are particularly relevant in NASH cirrhosis, 
where etiological therapies are as yet unavailable. Because a significant reduction in portal 
pressure is only achieved in ~50% of patients on NSBB (6), therapies that would enhance this 
effect are necessary.  
Emricasan, a pan-caspase inhibitor, had previously been shown (in an uncontrolled study) 
to result in clinically meaningful reductions in portal pressure in patients with compensated 
cirrhosis and severe portal hypertension (HVPG ≥ 12 mmHg) (9). However, in the current larger 
placebo-controlled study in patients with NASH cirrhosis and baseline HVPG ≥12 mmHg, 
emricasan failed to meet the primary endpoint of reduction in HVPG in the overall patient 
population. The significant decrease in caspase and other relevant biomarkers indicated target 
engagement, and ad-hoc analyses suggested that those with better caspase-related biomarker 
responses may have a greater decrease in HVPG (Table S4).   
Although the change in HVPG was not significant overall, there was evidence of a small 
treatment effect in the compensated subgroup (planned a alysis) in whom a trend for a greater 
reduction in HVPG with emricasan was observed, and baseline HVPG appeared to be the main 
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variable predicting response. In these subjects, ad-hoc analyses demonstrated that higher baseline 
HVPG (at a cut-off of 16 mmHg which represented the median value) was associated with 
greater reduction in HVPG. An HVPG greater than 16 mmHg has clinical relevance as it has 
been shown to predict decompensation in cirrhosis patients who already have clinically 
significant portal hypertension (11, 14, 15). In this study, the adjusted mean reduction in HVPG 
observed in compensated patients with HVPG ≥16 mmHg was -2.2 mmHg compared to placebo. 
This degree of reduction in HVPG might be important s reductions in HVPG as small as 1 
mmHg have recently been shown to be associated with lower decompensation/death rates (16). 
However, it is also important to note that these ad-hoc subgroup analyses must be interpreted 
with caution, given the possibility of false positives by chance alone from multiple comparisons. 
In patients with severe portal hypertension, increased portal blood flow plays a major role 
in maintaining and aggravating the portal hypertensive tate (15, 17). Therefore, one could 
speculate that the mechanism by which emricasan could have a portal pressure-reducing effect 
would be through a decrease in portal blood flow. In fact, a previous study in patients with 
cirrhosis (due to alcohol or hepatitis C) had shown that increased caspase activation and 
apoptosis resulted in vasoactive particles that decreased blood pressure and increased portal 
blood flow thereby worsening portal hypertension (18). Although emricasan treated-groups 
tended to have a smaller reduction in blood pressur compared to placebo, the significant 
improvement in aminotransferases suggests an intrahepatic rather than an extrahepatic effect. 
This would be consistent with a study in rats with CCl4-induced cirrhosis and ascites in which 
emricasan (for 7 days) was associated with improved li r function, reduced hepatic 
inflammation, and reduced fibrosis (through improvement of hepatocyte phenotype and 
modification of the hepatocyte secretome) without changes in portal blood flow (8). 
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Furthermore, another study in mice with bile duct ligation-induced cirrhosis showed that long-
term (20 days) treatment with emricasan reduced portal p essure and improved survival, with 
decrease in hepatocellular cell death and circulating microparticles, consistent with a decrease in 
liver injury (7).  
Because there may be a mechanistic explanation for a p tal-pressure lowering effect of 
emricasan and because there was a trend for a small treatment effect in compensated patients, the 
lack of a significant effect of emricasan on HVPG in the overall patient population may have 
been due to an unexpected high placebo response rate in decompensated patients, for which there 
is no clear explanation.  Although itt could be hypothesized that the presence of shunting (more 
prominent in decompensated patients) or down-regulation of organic anion-transporting 
polypeptide transporters (19) decreased emricasan to target cells, this would not be consistent 
with a seemingly larger effect in compensated patients with varices or with higher baseline 
HVPG. The fact that reductions in caspases and aminotra sferases were transient (despite 
continuation of emricasan) may suggest that effects on portal hypertension could also be 
transient, which could explain the differences between the initial exploratory study (with only 28 
days of emricasan) (9) and the current study.  
From a safety and tolerability perspective, emricasan appeared to be generally safe and 
well-tolerated with no specific safety signal identified. More definitive conclusions on the 
presence (or absence) of a concerning safety issue gen rally require substantially more subjects 
than the number enrolled in this study as well as evaluation over a longer time frame. However, 
no TEAE was clearly attributable to emricasan, and lthough there was a trend towards more 
serious and severe TEAEs, the absolute numerical difference was small. The incidence of all 
frequent TEAEs (occurring in >5% of subjects) was relatively low (generally <15-20%) in this 
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study and within the range expected in clinical trials and considering the patient population under 
evaluation (with cirrhosis and severe portal hypertension).   
Independent of the lack of a significant overall effect of emricasan on HVPG, this study 
provides invaluable data regarding the natural history of compensated (and decompensated) 
NASH cirrhosis, including the relatively low rate of clinical events over a median follow-up of 
almost a year in this patient population. Emricasan did not have an effect on the development of 
clinically relevant decompensation events; however, the study was very underpowered to detect 
any potential difference in decompensation events. This underscores the challenge of using a 
clinical outcome endpoint in patients with compensated NASH cirrhosis. Because of this, we 
used HVPG as the primary endpoint for this study, since HVPG could be a strong surrogate of 
clinical outcomes in patients with compensated cirrhosis, and the large numbers of patients and 
long duration of follow-up that would be needed in tr als with a primary endpoint of clinical 
outcomes could be impractical to conduct for initial regulatory approval. Including MELD or 
Child-Pugh progression as part of a composite clinical endpoint could increase the event rate. 
Finally, the data in the placebo group highlights te challenges of large placebo effects that have 
been previously observed in patients with compensatd NASH cirrhosis (e.g. simtuzumab) (20), 
which could impact sample sizes required for future studies in this patient population.   
In summary, this randomized, multicenter, double-blind, placebo-controlled study of 
patients with NASH cirrhosis (primarily compensated) and severe portal hypertension 
demonstrated that emricasan was not associated with a s gnificant reduction in HVPG or the 
incidence of decompensation, despite evidence of target engagement (decrease in caspases). 
However, it appeared to have a small effect in reducing HVPG in compensated patients, 
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especially those with higher baseline HVPG (threshold 16 mmHg), although the exact 
mechanism (if a true effect) is unclear.  
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Table 1. Subject demographics and baseline characteristics 
 
















Age (years) 60.2 (8.8) 62.0 (8.8) 59.5 (9.5) 60.6 (9.0) 61.4 (7.9) 
Female 37 (56.9%) 35 (53.8%) 33 (50.0%) 105 (53.6%) 45 (67.2%) 
Race (Caucasian) 58 (89.2%) 58 (89.2%) 60 (90.9%) 176 (89.8%) 64 (95.5%) 
BMI (kg/m 2) 35.3 (7.3) 34.4 (6.2) 35.6 (5.9) 35.1 (6.5) 35.9 (7. ) 
Diabetes mellitus  52 (80.0%) 52 (80.0%) 47 (71.2%) 151 (77.0%) 56 (83.6%) 
Hypertension 50 (76.9%) 49 (75.4%) 51 (77.3%) 150 (76.5%) 50 (74.6%) 
Compensated 49 (75.4%) 49 (75.4%) 48 (72.7%) 146 (74.5%) 55 (82.1%) 
Varices Absent 16 (32.7%) 12 (24.5%) 14 (29.2%) 42 (28.8%) 16 (29.1%) 
Varices Present 33 (67.3%) 37 (75.5%) 34 (70.8%) 104 (71.2%) 39 (70.9%) 
Decompensated 16 (24.6%) 16 (24.6%) 18 (27.3%) 50 (25.5%) 12 (17.9%) 
Varices Present 13 (81.3%) 13 (81.3%) 13 (72.2%) 39 (78.0%) 8 (66.7%) 
Prior VH 7 (43.8%) 5 (31.3%) 3 (16.7%) 15 (30.0%) 2 (16.7%) 
Ascites (treated) 7 (43.8%) 4 (25.0%) 9 (50.0%) 20 (40.0%) 5 (41.7%) 
HE (history≥grade2) 2 (12.5%) 7 (43.8%) 6 (33.3%) 15 (30.0%) 5 (41.7%) 
NSBB use 28 (43.1%) 26 (40.0%) 26 (39.4%) 80 (40.8%) 27 (40.3%) 
Statin use 25 (38.5%) 26 (40.0%) 22 (33.3%) 73 (37.2%) 23 (34.3%) 
AST (U/L) 46 (22) 48 (18) 46 (20) 47 (20) 47 (18) 
ALT (U/L) 34 (17) 35 (13) 36 (16) 35 (15) 34 (17) 
Platelet (K/mm3) 102 (39) 107 (48) 91 (31) 100 (41) 95 (34) 
Child Pugh score 5.5 (1.0) 5.4 (0.7) 5.6 (0.9) 5.5 (0.8) 5.4 (0.8) 
MELD score 9.2 (2.7) 9.1 (2.2) 9.2 (2.5) 9.2 (2.5) 8.4 (2.5) 
Liver stiffness (kPa) 39.1 (18.1) 44.7 (21.1) 34.2 (17.3) 39.4 (19.3) 36.8 (18.9) 
Caspase 3/7 (RLU) 3195 (1143) 3243 (1339) 3355 (1553) 3265 (1351) 3558 (1601) 
cCK18 (U/L) 408 (311) 394 (197) 395 (214) 399 (245) 366 (194) 
flCK18 (U/L) 792 (389) 814 (416) 851 (489) 819 (432) 817 (479) 
HVPG (mmHg) 16.9 (3.6) 17.3 (3.3) 16.9 (3.8) 17.0 (3.5) 16.8 (3.7) 
%Excellent/very good/good 60 (92.3%) 60 (92.3%) 61 (92.4%) 181 (92.3%) 61 (91.0%) 
BMI = body mass index, VH = variceal hemorrhage, HE = hepatic encephalopathy, NSBB = non-selective beta-blocker 
*Continuous variables are expressed as mean (standard deviation) and categorical variables are 
expressed as the number of patients (percentage from total). 
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All Subjects (N=263) n=65 n=65 n=66 N=196 N=67 
Baseline 16.9 (3.6) 17.3 (3.3) 16.9 (3.8) 17.0 (3.5) 16.8 (3.7) 
Mean (SD) CFB -0.48 (3.4) -0.81 (3.7) -0.70 (3.4) -0.66 (3.5) -0.18 (3.0) 
Difference in LSM (CI) -0.21 (-1.4,0.95) -0.45 (-1.6,0.72) -0.58 (-1.7,0.59) -0.44 (-1.37,0.49) 
 
p-value* 0.97 0.79 0.65 0.35  
Compensated  n=46 n=47 n=42 N=135 N=53 
Baseline 16.8 (3.7) 17.2 (3.1) 16.8 (3.6) 17.0 (3.5) 16.5 (3.6) 
Mean CFB -0.79 (3.5) -0.91 (3.2) -0.44 (3.7) -0.73 (3.4) +0.33 (2.3) 
Difference in LSM (CI) -1.0 (-2.3,0.19) -1.1 (-2.3,0.16) -0.70 (-2.0,0.56) -0.94 (-1.9,0.04)  
p-value∫ 0.10 0.09 0.28 0.06  
Compensated, no varices n=15 n=12 n=12 N=39 N=16 
Baseline 16.9 (4.6) 16.2 (2.7) 14.5 (2.9) 15.9 (3.6) 15.8 (2.6) 
Mean CFB -0.83 (3.5) -1.4 (3.1) +0.95 (4.6) -0.46 (3.8) -0.44 (2.4) 
Difference in LSM (CI) -0.31 (-2.8,2.2) -0.95 (-3.6,1.7) +1.3 (-1.4,4.0) 0.00 (-2.1,2.1)  
p-value∫ 0.80 0.48 0.33 1.0  
Compensated, varices n=31 n=35 n=30 N=96 N=37 
Baseline 16.8 (3.3) 17.6 (3.2) 17.7 (3.6) 17.4 (3.4) 16.8 (3.9) 
Mean CFB -0.77 (3.6) -0.74 (3.2) -1.0 (3.3) -0.83 (3.3) +0.66 (2.2) 
Difference in LSM (CI) -1.4 (-2.8,0) -1.2 (-2.5,0.19) -1.4 (-2.8,0.02) -1.3 (-2.4,-0.21)  
p-value∫ 0.05 0.09 0.05 0.02  
Compensated HVPG≥16 n=26 n=30 n=21 N=77 N=26 
Baseline 19.2 (3.0) 19.1 (2.4) 19.8 (2.5) 19.4 (2.6) 19.4 (2.8) 
Mean CFB -1.63 (3.9) -1.67 (2.8) -1.59 (3.2) -1.64 (3.2) +0.52 (2.1) 
Difference in LSM (CI) -2.2 (-3.8,-0.5) -2.3 (-3.8,-0.7) -2.0 (-3.8,-0.3) -2.2 (-3.5,-0.8)  
p-value∫ 0.01 0.006 0.02 0.002  
Decompensated  n=15 n=15 n=14 N=44 N=11 
Baseline 17.3 (3.4) 18.0 (3.7) 15.8 (3.2) 17.1 (3.5) 18.2 (2.7) 
Mean CFB +0.50 (2.7) -0.50 (5.1) -1.5 (2.0) -0.47 (3.5) -2.6 (4.6) 
Difference in LSM (CI) +2.9 (-0.10,5.9) +2.1 (-0.88,5.0) +0.52 (-2.6,3.6) +1.9 (-0.64,4.5)  
p-value∫ 0.06 0.16 0.74 0.14  
NSBB use n=27 n=25 n=22 n=74 N=26 
Baseline 16.8 (3.9) 17.9 (3.6) 17.2 (3.1) 17.3 (3.6) 16.7 (4.1) 
Mean CFB -1.0 (3.0) -0.68 (4.0) -1.2 (2.7) -1.0 (3.3) +0.10 (2.8) 
Difference in LSM (CI) -1.1 (-2.7,0.61) -0.46 (-2.2,1.3) -1.2 (-2.9,0.60) -0.90 (-2.3,0.50)  
p-value∫ 0.21 0.60 0.19 0.20  
No NSBB use n=34 n=37 n=34 N=105 N=38 
Baseline 17.0 (3.4) 17.1 (3.0) 16.1 (3.8) 16.7 (3.4) 16.8 (3.1) 
Mean CFB -0.04 (3.6) -0.91 (3.4) -0.35 (3.8) -0.45 (3.6) -0.37 (3.2) 
Difference in LSM (CI) +0.37 (-1.2,2.0) -0.48 (-2.0,1.1) -0.16 (-1.8,1.4) -0.10 (-1.4,1.2)  
p-value∫ 0.65 0.55 0.84 0.88  
CFB = change from baseline (unadjusted mean), LSM = least squares mean, CI = 95% confidence intervals. 
NSBB = non-selective beta-blocker.  Difference in LSM is based on adjusted means 
*p-value vs. placebo based on ANCOVA adjusting for baseline compensation status, baseline NSBB use, and baseline HVPG, 









Table 3. Clinical outcome events and MELD and Child-Pugh progression. Clinical outcome 
events during the study in all subjects and compensat d and decompensated subgroups. MELD 
progression in all subjects and in compensated subjects with MELD ≤12. Child-Pugh 












All Subjects n=65 n=65 n=66 N=196 N=67 
Total Events 7 (10.8%) 9 (13.8%) 4 (6.1%) 20 (10.2%) 7 (10.4%) 
    p=0.95  
Compensated* n=49 n=49 n=48 N=146 N=55 
Any new event 5 (10.2%) 4 (8.2%) 1 (2.1%) 10 (6.8%) 4 (7.3%) 
    p=0.92  
New VH 2 (4.1%) 3 (6.1%) 0 5 (3.4%) 0 
New ascites 1 (2.0%) 2 (4.1%) 1 (2.1%) 4 (2.7%) 4 (7.3%) 
New HE 2 (4.1%) 1 (2.0%) 0 3 (2.1%) 1 (1.8) % 
Decompensated§ n=16 n=16 n=18 N=50 N=12 
Any new or worsening event 2 (12.5%) 5 (31.3%) 3 (16.7%) 10 (20.0%) 3 (25.0%) 
    p=0.70  
- New event 1 (6.3%) 3 (18.8%) 2 (11.1%) 6 (12.0%) 2 (16.7%) 
- Worsening of existing 
event∫ 1 (6.3%) 2 (12.5%) 1 (5.6%) 4 (8.0%) 1 (13.9%) 
       
≥4-point MELD progression 
in All Subjects n=65 n=65 n=66 N=196 N=67 
Week 24 15 (23.1) 8 (12.3) 8 (12.1) 31 (15.8) 10 (14.9) 
    p=0.86  
Week 48 15 (23.1) 10 (15.4) 14 (21.2) 39 (19.9) 16 (23.9) 
    p=0.49  
Progress to MELD ≥15 in 
Compensated MELD ≤12 n=43 n=45 n=45 N=133 N=53 
Week 24 7 (16.3) 2 (4.4) 1 (2.2) 10 (7.5) 2 (3.8) 
    p=0.35  
Week 48 7 (16.3) 2 (4.4) 3 (6.7) 12 (9.0) 4 (7.5) 
    p=0.75  
≥2-point CP progression in 
All Subjects n=65 n=65 n=66 N=196 N=67 
Week 24 8 (12.3) 2 (3.1) 3 (4.5) 13 (6.6) 4 (6.0) 
    p=0.85  
30 
 
Week 48 9 (13.8) 7 (10.8) 6 (9.1) 22 (11.2) 12 (17.9) 
    p=0.16  
Progression to CP B in 
baseline CP A n=56 n=59 n=54 N=169 N=61 
Week 24 13 (23.2) 5 (8.5) 7 (13.0) 25 (14.8) 10 (16.4) 
    p=0.77  
Week 48 13 (23.2) 13 (22.0) 12 (22.2) 38 (22.5) 15 (24.6) 
    p=0.74  
VH = variceal hemorrhage, HE = hepatic encephalopathy 
*1 subject (25 mg) had new ascites, HE, and VH, and 1 subject (placebo) had new ascites and HE.  
§1 subject (50 mg) with prior VH had new and worsening ascites. 




























All EMR v 
PBO 
Systolic BP (mmHg)  128.9 (16.2) 128.8 (12.9) 126.8 (13.6) 128.1 (14.3) 132.8 (17.2)  
Change at Week 24 (N=243) -2.8 (15.8) -3.1 (14.3) +0.7 (13.7) -1.7 (14.6) -4.7 (15.6) <0.001 
Mean arterial pressure 
(mmHg) 90.8 (10.7) 91.1 (8.2) 88.8 (8.4) 90.2 (9.1) 92.9 (10.8)  
Change at Week 24 (N=243) -2.3 (11.0) -2.4 (9.1) -0.01 (9.6) -1.6 (9.9) -3.3 (10.9) 0.001 
Heart rate (bpm) 69.8 (9.4) 72.4 (12.5) 69.4 (9.4) 70.6 (10.6) 71.7 (10.1)  
Change at Week 24 (N=243) +0.1 (8.9) -1.0 (8.5) +0.7 (9.0) -0.1 (8.8) -1.5 (8.9) 0.002 
Body weight (kg) 98.5 (23.9) 99.4 (23.4) 104.6 (22.7) 100.8 (23.3) 98.7 (23.4)  
Change at Week 24 (N=242) +0.11 (4.4) -0.04 (3.9) -0.04 (4.2) +0.01 (4.1) +0.02 (4.4) 0.399 
Liver stiffness (kPa) 40.9 (18.8) 47.2 (20.8) 32.2 (16.5) 40.4 (19.7) 34.5 (17.5)  
Change at Week 24 (N=176) -3.1 (18.7) -6.7 (22.9) -0.9 (14.5) -3.6 (19.1) -0.3 (14.3) <0.001 
Platelet (K/mm3) 105 (41) 108 (49) 92 (32) 102 (42) 95 (35)  
 Change at Week 24 (N=229) -3.5 (19.8) -7.3 (22.8) -4.6 (17.4) -5.2 (20.1) -4.6 (13.7) 0.235 
MELD score 9.1 (2.8) 9.0 (2.2) 9.1 (2.0) 9.1 (2.3) 8.5 (2.6)  
Change at Week 24 (N=234) +0.1 (2.1) +0.0 (1.7) +0.2 (1.4) +0.1 (1.8) +0.4 (2.2) 0.148 
Child Pugh score 5.5 (1.0) 5.4 (0.7) 5.6 (0.9) 5.5 (0.8) 5.4 (0.8)  
Change at Week 24 (N=236) +0.14 (0.55) +0.15 (0.58) +0.05 (0.48) +0.12 (0.54) +0.31 (0.56) 0.087 
Total bilirubin (µmol/L) 20.5 (12.0) 18.8 (10.3) 20.5 (17.1) 20.5 (13.7) 17.1 (12.0)  
Change at Week 24 (N=243) -0.51 (6.7) -0.51 (6.3) -0.17 (5.3) -0.34 (6.2) +0.34 (6.0) 0.002 
Albumin (g/L) 40.0 (5.0) 40.0 (4.0) 40.0 (5.0) 40.0 (4.0) 39.0 (4.0)  
Change at Week 24 (N=243) -1.0 (2.0) -1.0 (3.0) -1.0 (2.0) -1.0 (2.0) -1.0 (3.0) 0.399 
INR 1.2 (0.2) 1.2 (0.1) 1.2 (0.1) 1.2 (0.1) 1.2 (0.1)  
Change at Week 24 (N=240) 0.00 (0.10) +0.04 (0.11) +0.02 (0.07) +0.02 (0.10) +0.02 (0.07) 0.399 
Creatinine (µmol/L) 61.9 (17.7) 61.9 (17.7) 61.9 (17.7) 61.9 (17.7) 61.9 (17.7)  







Table 5. Summary of treatment-emergent adverse events (TEAEs) in all subjects 
 
















All TEAEs 59 (90.8) 62 (95.4) 57 (86.4) 178 (90.8) 61 (91.0) 
Serious TEAEs 14 (21.5) 22 (33.8) 20 (30.3) 56 (28.6) 15 (22.4) 
Severe TEAEs 13 (20.0) 16 (24.6) 16 (24.2) 45 (23.0) 13 (19.4) 
Related to study drug 14 (21.5) 18 (27.7) 23 (34.8) 55 (28.1) 18 (26.9) 
Study discontinuation 6 (9.2) 4 (6.2) 7 (10.6) 17 (8.7) 3 (4.5) 
Study drug stopped 4 (6.2) 3 (4.6) 5 (7.6) 12 (6.1) 4 (6.0) 
Frequent TEAEs (>5%*)      
Edema peripheral 9 (13.8) 14 (21.5) 8 (12.1) 31 (15.8) 8 (11.9) 
Urinary tract infection 9 (13.8) 11 (16.9) 6 (9.1) 26 (13.3) 10 (14.9) 
Diarrhea 10 (15.4) 7 (10.8) 6 (9.1) 23 (11.7) 13 (19.4) 
Nausea 6 (9.2) 9 (13.8) 8 (12.1) 23 (11.7) 11 (16.4) 
Abdominal pain upper 4 (6.2) 7 (10.8) 8 (12.1) 19 (9.7) 3 (4.5) 
Muscle spasms 7 (10.8) 6 (9.2) 5 (7.6) 18 (9.2) 2 (3.0) 
Ascites 4 (6.2) 9 (13.8) 4 (6.1) 17 (8.7) 8 (11.9) 
Headache 3 (4.6) 7 (10.8) 7 (10.6) 17 (8.7) 5 (7.5) 
Bronchitis 6 (9.2) 2 (3.1) 7 (10.6) 15 (7.7) 3 (4.5) 
Fatigue 3 (4.6) 6 (9.2) 6 (9.1) 15 (7.7) 6 (9.0) 
Hepatic encephalopathy 5 (7.7) 5 (7.7) 5 (7.6) 15 (7.7) 12 (17.9) 
Abdominal pain 7 (10.8) 2 (3.1) 5 (7.6) 14 (7.1) 7 (10.4) 
Upper resp tract infection 4 (6.2) 4 (6.2) 4 (6.1) 12 (6.1) 5 (7.5) 
Asthenia 6 (9.2) 1 (1.5) 4 (6.1) 11 (5.6) 3 (4.5) 
Cellulitis 3 (4.6) 4 (6.2) 4 (6.1) 11 (5.6) 4 (6.0) 
Anemia 4 (6.2) 2 (3.1) 4 (6.1) 10 (5.1) 10 (14.9) 
Dizziness 4 (6.2) 2 (3.1) 4 (6.1) 10 (5.1) 6 (9.0) 
Vomiting 3 (4.6) 4 (6.2) 3 (4.5) 10 (5.1) 4 (6.0) 
Back pain 3 (4.6) 4 (6.2) 2 (3.0) 9 (4.6) 8 (11.9) 
Fall 2 (3.1) 4 (6.2) 3 (4.5) 9 (4.6) 6 (9.0) 
Nasopharyngitis 1 (1.5) 4 (6.2) 4 (6.1) 9 (4.6) 5 (7.5) 
Constipation 3 (4.6) 4 (6.2) 1 (1.5) 8 (4.1) 6 (9.0) 






Fig. 1. Forest plot of change in HVPG at week 24 in all subjects and subgroups. Small solid 
rectangular boxes reflect point estimate of least squares mean difference between emricasan dose 
group compared to placebo and bars represent 95% confidence intervals.  
 
Fig. 2. Change in HVPG at week 24 vs. baseline HVPG by treatment group in all subjects 
and compensated subjects. Line represents regression line, shaded area shows 95% confidence 
interval, and r value indicates correlation coefficient. (A) All subjects and (B) Compensated 
subjects.  
 
Fig. 3. Forest plot of change in caspase 3/7, cCK18, flCK18, ALT, and AST at week 24 and 
week 48 in all subjects. Small solid rectangular boxes reflect point estimae of least squares 
mean difference between emricasan dose group compared to placebo and bars represent 95% 

























Fig. 3.  






 (B) Week 48 
 
Highlights 
- Phase III, multicenter study, comparing emricasan, (a caspase inhibitor) at 3 different 
doses vs. placebo in patients with NASH cirrhosis and severe portal hypertension 
- Despite evidence of target engagement, emricasan did not reduce portal hypertension in 
the overall study population 
- The portal pressure-reducing effect may be more evident in latter stages of portal 
hypertension 
- Treatment-emergent adverse events were similar between emricasan and placebo 
 
